BiotechMashup

A new clinical trial, EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), is being launched in order to compare drug-eluting stents to coronary artery bypass graft surgery in patients with left main coronary artery disease.

A new study compares the safety and efficacy of heart bypass surgery to angioplasty with drug-eluting stents in patients with left main coronary artery disease, a diagnosis affecting thousands of individuals. Drug-eluting stents are treated with a medication that helps keep the artery from reclosing.

(University of California - Los Angeles) A new UCLA study compares the safety and efficacy of heart bypass surgery to angioplasty with drug-eluting stents in patients with left main coronary artery disease, a diagnosis affecting thousands of individuals. Drug-eluting stents are treated with a medication that helps keep the artery from reclosing.

Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research, according to results of a multicenter, retrospective study.

(Wiley-Blackwell) Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

(Emory University) Hybrid revascularization is a combination of coronary artery bypass surgery and percutaneous coronary intervention.Researchers will report on outcomes from 21 Emory patients with blockages in the left main coronary artery treated using hybrid revascularization.

(Cardiovascular Research Foundation) Researchers have found that polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared to paclitaxel-eluting stents with permanent polymers. Results of the NEXT trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. NEXT is a prospective, randomized trial comparing a polymer-free amphilimus-eluting stent to a paclitaxel-eluting stent.

Heart bypass surgery is considered the gold standard for most patients with left main coronary artery disease, one of the most serious types of heart disease and one that affects thousands. But a new study reports favorable long-term outcomes for lower-risk patients with this condition who underwent angioplasty with medication-coated stents, rather than bypass surgery.

(University of California - Los Angeles Health Sciences) Heart bypass surgery is considered the gold standard for most patients with left main coronary artery disease, one of the most serious types of heart disease and one that affects thousands. But a new UCLA study reports favorable long-term outcomes for lower-risk patients with this condition who underwent angioplasty with medication-coated stents, rather than bypass surgery.